Future Fields vs Ankr

Side-by-side comparison of AI visibility scores, market position, and capabilities

Ankr leads in AI visibility (33 vs 26)
Future Fields logo

Future Fields

EmergingHealthcare

General

Precision fermentation biotech producing animal-free growth factors for cultivated meat and cell therapy; Drosophila expression system enabling lower-cost recombinant protein production.

AI VisibilityBeta
Overall Score
D26
Category Rank
#533 of 1158
AI Consensus
79%
Trend
up
Per Platform
ChatGPT
22
Perplexity
23
Gemini
25

About

Future Fields is a precision fermentation biotechnology company producing recombinant growth factors and proteins for the cultivated meat and cell therapy industries — using Drosophila (fruit fly) expression system to manufacture animal-free, scalable alternatives to animal serum-derived growth factors that are a major cost driver in cell-based biotech production. Founded in 2019 by Matthew Anderson-Baron and Jalene Anderson-Baron in Edmonton, Canada, Future Fields has raised approximately $11 million and targets the cultivated meat industry and cell therapy manufacturers who need cost-effective, animal-free growth factor supply.\n\nFuture Fields' EntoEngine platform uses genetically modified Drosophila to produce recombinant proteins (growth factors like FGF, EGF, IGF, TGF) at lower cost than mammalian cell expression systems — the Drosophila system is faster to scale, has lower infrastructure requirements, and produces proteins at commercially viable price points. For the cultivated meat industry, growth factors represent one of the largest cost components in cell culture media, and animal-free sources are preferred both for cost and for meeting "animal-free" product claims.\n\nIn 2025, Future Fields competes with Mycenax Biotech, Ajinomoto, and conventional growth factor suppliers for the cell culture media market. The cultivated meat industry has faced headwinds as commercialization timelines have extended and regulatory approvals have been slower than anticipated, but cell therapy (CAR-T, stem cell therapy, gene therapy) manufacturing represents a large adjacent market for Future Fields' growth factors. The 2025 strategy focuses on growing revenue from cell therapy manufacturers who need GMP-grade recombinant proteins, continuing to reduce production costs, and positioning as the commercial-scale alternative to FBS-derived growth factors.

Full profile
Ankr logo

Ankr

EmergingWeb3

Multi-Chain RPC Infrastructure

Decentralized Web3 infrastructure with RPC node access across 30+ blockchains; globally distributed nodes reduce latency; premium dedicated nodes for apps needing guaranteed throughput.

AI VisibilityBeta
Overall Score
D33
Category Rank
#1 of 1
AI Consensus
56%
Trend
up
Per Platform
ChatGPT
40
Perplexity
40
Gemini
29

About

Ankr is a Web3 infrastructure platform offering remote procedure call node access to more than 30 blockchain networks through a globally distributed network of nodes run by independent operators. Unlike centralized providers that operate their own data centers exclusively, Ankr's decentralized architecture routes requests across geographically distributed nodes, improving latency for users in regions underserved by US- or EU-centric infrastructure. Its public free-tier RPC endpoints — available for Ethereum, BNB Chain, Polygon, Avalanche, Fantom, and dozens of others — have made Ankr one of the most widely used infrastructure providers in the multi-chain developer ecosystem.

Full profile

AI Visibility Head-to-Head

26
Overall Score
33
#533
Category Rank
#1
79
AI Consensus
56
up
Trend
up
22
ChatGPT
40
23
Perplexity
40
25
Gemini
29
29
Claude
25
20
Grok
40

Capabilities & Ecosystem

Capabilities

Only Ankr
Multi-Chain RPC Infrastructure

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.